24 April 2013Americas

FTC critical of pay-for-delay in annual report

The US Federal Trade Commission (FTC) has published its annual report for 2012, in which it remains critical of “pay-for-delay” patent settlements.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Ability to settle cases influences generic patent challenges, study finds

25 July 2013 A white paper suggests that patent case settlements between originator pharmaceutical companies and their generic competitors may be beneficial to drug consumers.

Big Pharma

European Commission targets alleged ‘pay-for-delay’ with pharma fines

20 June 2013 The European Commission’s competition directorate has levied fines totalling €146 million ($195 million) against originator pharmaceutical company Lundbeck and several producers of generics drugs.

Americas

US Supreme Court backs ‘rule-of-reason’ for pay-for-delay

17 June 2013 A majority of the US Supreme Court has ruled that the US Federal Trade Commission should be able to challenge so-called ‘pay-for-delay’ patent litigation settlements on antitrust grounds.

More features

The Quintara decision: Defining trade secrets in federal cases

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

FTC critical of pay-for-delay in annual report

More on this story

Editor's picks

Editor's picks

More features